Search This Blog

Wednesday, April 30, 2025

Bausch + Lomb (NYSE:BLCO) Misses Q1 Sales Targets

 Eyecare company Bausch + Lomb (NYSE:BLCO) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3.5% year on year to $1.14 billion. On the other hand, the company’s full-year revenue guidance of $5.05 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP loss of $0.15 per share was significantly below analysts’ consensus estimates.

Revenue: $1.14 billion vs analyst estimates of $1.15 billion (3.5% year-on-year growth, 0.7% miss)

  • Adjusted EPS: -$0.15 vs analyst estimates of $0.02 (significant miss)

  • Adjusted EBITDA: $126 million vs analyst estimates of $163.4 million (11.1% margin, 22.9% miss)

  • The company lifted its revenue guidance for the full year to $5.05 billion at the midpoint from $4.98 billion, a 1.5% increase

  • EBITDA guidance for the full year is $875 million at the midpoint, below analyst estimates of $922.4 million

  • Operating Margin: -7.3%, down from 0.5% in the same quarter last year

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.